toripalimab + surufatinib + chemoradiotherapy

This combination therapy regimen is being evaluated for the treatment of limited-stage small cell lung cancer (LS-SCLC). It consists of **toripalimab**, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, and **surufatinib**, a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR 1, 2, and 3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF-1R). The regimen is administered concurrently with standard chemoradiotherapy, which typically includes etoposide combined with cisplatin or carboplatin and thoracic radiation. The combination aims to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and the modulation of the tumor immune microenvironment alongside cytotoxic therapy to improve survival outcomes in patients with LS-SCLC.

Other names

Toripalimab and Surufatinib with Chemoradiotherapy in LS-SCLC